10x Genomics (NASDAQ:TXG) Announces Quarterly Earnings Results, Beats Estimates By $0.06 EPS

10x Genomics (NASDAQ:TXG) issued its quarterly earnings results on Thursday. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.06, Zacks reports. The company had revenue of $166.03 million for the quarter, compared to the consensus estimate of $160.35 million. 10x Genomics had a negative return on equity of 11.50% and a negative net margin of 11.89%.10x Genomics’s revenue was up .6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.40) EPS.

Here are the key takeaways from 10x Genomics’ conference call:

• Single-cell and spatial consumables showed strong momentum — reaction volumes grew double-digits driven by adoption of FLEX APEX, and spatial consumables rose 14% as Xenium adoption expanded across customers.
• Management reinstated full-year 2026 revenue guidance of $600–$625M, implying roughly 0–4% growth (ex‑litigation) with the midpoint assuming flat Chromium consumables and double-digit spatial growth.
• Instrument revenue remains a drag, down 36% in Q4 (Chromium down 44%), and the company expects ongoing capital expenditure constraints to keep instrument sales pressured in 2026.
• Financials strengthened — cash rose by about $130M to $523M, Q4 gross margin was 68%, and operating expenses fell 18%, giving the company more flexibility to invest while managing costs.

10x Genomics Stock Performance

10x Genomics stock opened at $17.51 on Friday. The company has a market capitalization of $2.22 billion, a P/E ratio of -28.24 and a beta of 2.24. 10x Genomics has a fifty-two week low of $6.78 and a fifty-two week high of $23.56. The stock has a 50-day simple moving average of $18.66 and a 200-day simple moving average of $15.57.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. UBS Group raised their target price on shares of 10x Genomics from $13.00 to $14.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Piper Sandler lifted their price objective on shares of 10x Genomics from $15.00 to $19.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 11th. Barclays increased their target price on 10x Genomics from $17.00 to $22.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 10x Genomics in a report on Monday, December 22nd. Finally, Wall Street Zen downgraded 10x Genomics from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Three research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $17.04.

10x Genomics News Summary

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: Q4 results beat expectations: 10x reported $0.13 loss vs. a consensus loss of $0.19 and revenue of $166.0M vs. ~$160.4M. EPS improved materially vs. last year. This shows execution and margin improvement momentum. MarketBeat: Q4 release
• Positive Sentiment: Strategic research collaboration: Coverage highlights a UK-backed PharosAI project using 10x’s Xenium platform — a win that could expand commercial demand in large-scale cancer research and improve the long-term growth case. Yahoo: PharosAI/Xenium
• Neutral Sentiment: Analyst posture: TD Cowen kept a Hold rating but raised the price target to $19, citing the Q4 beat but limited visibility into 2026 growth and valuation upside — supportive of the shares but not a bullish endorsement. TipRanks: TD Cowen note
• Neutral Sentiment: Official outlook: Management issued 2026 revenue guidance of $600M–$625M (consensus ~ $624M). The range technically overlaps estimates but centers near the low-to-mid point, leaving limited upside for analysts to raise numbers immediately. PR Newswire: Q4 & outlook
• Neutral Sentiment: Short-interest data flagged in feeds appears unreliable/zeroed and should not be read as a meaningful change in bearish positioning. (Reported figures show zeros/NaN.)
• Negative Sentiment: New pricing strategy introduces execution risk: coverage notes that a new pricing approach is debuting this quarter — investors are treating it as an “earnings test” because it could pressure near-term revenue or adoption if customers resist or if per-unit ASPs decline. Investing.com: pricing strategy
• Negative Sentiment: Visibility and profitability remain a concern: despite the beat, 10x still posts negative net margin and negative ROE, and consensus estimates still show fiscal-year EPS well below breakeven — factors that cap valuation multiple expansion near-term.

Insider Buying and Selling

In related news, CFO Adam Taich sold 11,888 shares of the firm’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $19.00, for a total transaction of $225,872.00. Following the transaction, the chief financial officer owned 297,385 shares of the company’s stock, valued at $5,650,315. This trade represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Benjamin J. Hindson sold 8,283 shares of the business’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $19.00, for a total value of $157,377.00. Following the completion of the transaction, the insider owned 432,605 shares in the company, valued at $8,219,495. This trade represents a 1.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 33,432 shares of company stock worth $635,208 in the last quarter. 9.39% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC lifted its holdings in shares of 10x Genomics by 241.3% during the second quarter. AQR Capital Management LLC now owns 4,137,801 shares of the company’s stock worth $47,916,000 after purchasing an additional 2,925,372 shares during the period. Millennium Management LLC raised its position in 10x Genomics by 84.7% during the 3rd quarter. Millennium Management LLC now owns 5,437,969 shares of the company’s stock worth $63,570,000 after buying an additional 2,494,142 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of 10x Genomics by 126.6% in the 3rd quarter. Wellington Management Group LLP now owns 4,285,628 shares of the company’s stock worth $50,099,000 after acquiring an additional 2,394,355 shares during the period. Quantinno Capital Management LP boosted its holdings in shares of 10x Genomics by 207.2% in the second quarter. Quantinno Capital Management LP now owns 2,233,526 shares of the company’s stock valued at $25,864,000 after acquiring an additional 1,506,530 shares in the last quarter. Finally, ARK Investment Management LLC increased its stake in shares of 10x Genomics by 6.6% during the fourth quarter. ARK Investment Management LLC now owns 12,667,369 shares of the company’s stock worth $206,605,000 after acquiring an additional 779,973 shares during the period. Institutional investors and hedge funds own 84.68% of the company’s stock.

About 10x Genomics

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.